Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells

Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells

Background/Aims: Blocking estrogen signaling with endocrine therapies (Tamoxifen or Fulverstrant) is an effective treatment for Estrogen Receptor-α positive (ER+) breast cancer tumours. Unfortunately, development of endocrine therapy resistance (ETR) is a frequent event resulting in disease relapse...

Full description

Bibliographic Details
Main Authors: Pratima Basak, Sumanta Chatterjee, Vasudeva Bhat, Alice Su, Hyerang Jin, Victoria Lee-Wing, Qian Liu, Pingzhao Hu, Leigh C Murphy, Afshin Raouf
Format: Article
Language:English
Published: Cell Physiol Biochem Press GmbH & Co KG 2018-11-01
Series:Cellular Physiology and Biochemistry
Subjects:
Tamoxifen Resistance
Fulvestrant (ICI) resistance
Endocrine Therapy resistance
H19
ERα
Notch signaling
C-MET signaling
ER+ breast cancers
Online Access:https://www.karger.com/Article/FullText/495643

Internet

https://www.karger.com/Article/FullText/495643

Similar Items